Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

Abstract excerpt

The prognosis for newly diagnosed multiple myeloma (NDMM) has improved with the advent of new agents, but outcome in some patients remains very poor. Identifying patients with high-risk disease early opens up the prospect of stratified treatment [ 1 , 2 , 3 ].

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors